J&J COVID-19 Vaccine Begins Final Stage of Clinical Trials
WEDNESDAY, Sept. 23, 2020 -- The final stage of clinical trials for Johnson & Johnson's COVID-19 vaccine have started, the company announced Tuesday.
The phase 3 trials will include 60,000 people and be the largest for a COVID-19 vaccine in the United States, The New York Times reported. Johnson & Johnson's final-stage trials began months after similar trials of other COVID-19 vaccines in the United States, but it may have some advantages over the other vaccines because it does not need to be stored in subzero temperatures and may require just one dose instead of two, according to experts.
"It would be fabulous if we had something at a single dose," because it could speed efforts to curb the pandemic, Judith Feinberg, M.D., vice chairwoman for research in medicine at West Virginia University, told The Times. She is not involved in the vaccine research.
Johnson & Johnson might know by the end of the year if the vaccine is safe and effective, Paul Stoffels, M.D., the company's chief scientific officer, said at a news conference on Tuesday, The Times reported.
© 2020 HealthDay. All rights reserved.
Posted: September 2020
Further Support and Information on COVID-19
Read this next
Stricter Vaccine Approval Rules Coming From FDA
WEDNESDAY, Sept. 23, 2020 -- Stricter guidelines for emergency authorization use of a vaccine against the new coronavirus could soon be issued by the U.S. Food and Drug...
As Flu Season Approaches, Clinicians Brace for Potential 'Twindemic'
WEDNESDAY, Sept. 23, 2020 -- Flu shots may be more important than ever this year, as COVID-19 presents new challenges for clinicians and communities this flu season. HD Live!...
U.S. COVID-19 Death Toll Hits 200,000 as Cases Climb in 22 States
WEDNESDAY, Sept. 23, 2020 -- The U.S. COVID-19 death toll reached the tragic milestone of 200,000 on Tuesday, with at least 22 states now reporting a rise in new cases. Just last...